In this issue:
HER2 discordance in breast cancer
Adding everolimus improves outcomes
Neoadjuvant lapatinib in HER2+ disease
Pertuzumab in metastatic disease
Who benefits from dose-dense chemo?
Favourable trends in EU breast cancer mortality
Ethnic inequalities in breast cancer survival
Regional recurrence in breast cancer
SLN biopsy of higher-risk tumours
Please login below to download this issue (PDF)